Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623324 · ClinicalTrials.gov registry record · Phase 2
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease
A Phase 2 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00623324 is a Phase 2 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT00623324, a Phase 2 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety, tolerability, efficacy and pharmacokinetics of aplindore in patients with early stage Parkinson's Disease (PD) who are not currently taking any dopamine agonists or who are able to wash off dopamine agonists for 14 days prior to baseline. Efficacy will be assessed using the UPDRS questionnaire including part 3 of the UPDRS (Motor). their level of sleepiness on a standardized rating scale (Epworth Sleepiness Scale) and their level of nausea daily. Safety endpoints will include adverse events (AEs), clinical laboratory data, vital signs (blood pressure, orthostatic blood pressure and heart rate), ECGs, physical examinations and self rated scales.
Interventions
- DRUG Placebo
- DRUG Aplindore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00623324
The ClinicalTrials.gov registry entry for NCT00623324 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00623324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00623324 about?
NCT00623324 is a clinical study titled "The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease". The purpose of this study is to demonstrate the safety, tolerability, efficacy and pharmacokinetics of aplindore in patients with early stage Parkinson's Disease (PD) who are not currently taking any dopamine agonists or who are able to wash off dopamine agonists for 14 days prior to baseline. Effic...
What is the current status of trial NCT00623324?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-01.
What interventions are being tested in trial NCT00623324?
The interventions under investigation include: Placebo (DRUG), Aplindore (DRUG).
Who is sponsoring clinical trial NCT00623324?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.